Set Your Location to See Relevant Information

Setting your location helps us to show you nearby providers and locations based on your healthcare needs.

Adaptive COVID-19 Treatment Trial 4 (ACTT-4), NIH

Objective

Goal: To evaluate the clinical efficacy of baricitinib + remdesivir versus dexamethasone + remdesivir as assessed by the mechanical ventilation free survival by Day 29.

  • Phase III, randomized, double-blind, placebo-controlled trial.
  • Subjects will be assessed daily while hospitalized. If the subjects are discharged from the hospital, they will have a study visit at Days 15, 22, and 29.
  • Multicenter trial with 100 centers globally and 1500 subject enrollment goal.
Investigator

Diego Lopez de Castilla, MD, EvergreenHealth Infectious Disease Care

Clinical Trial Categories

  • COVID-19
Contact
EvergreenHealth Research Services at 425-899-5385
or EvergreenResearch@evergreenhealth.com

Contact Us

Call us at (425) 899-5385 or use our online information request form.

Online Form